{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:17:27Z","timestamp":1715955447845},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":323,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2001,2]]},"abstract":"<jats:p>. The efficacy of Vigam\u2010S, a highly purified intravenous immunoglobulin, was investigated by an open, noncomparative study in 20 adults with chronic idiopathic thrombocytopenic purpura (ITP). Fifteen patients responded to the initial 3\u2010day infusion of 0\u00b74\u2003g\u2003kg\u2003<jats:sup>\u22121<\/jats:sup>\u2003day<jats:sup>\u22121<\/jats:sup> by exhibiting an incremental increase in platelet count of \u2265\u200a30\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup>, in eight of whom platelet count normalized (&gt;\u2003150\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup>). The peak platelet count for responders on day 4 was 163\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup> (baseline\u2003=\u200318\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup>). No benefit was derived from an extra 2\u2003days infusion in nonresponders. Further treatment (either a single 0\u00b78\u2003g\u2003kg<jats:sup>\u22121<\/jats:sup> dose or another 3\u2010day infusion) given to responders when platelet counts fell below 30\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup> was effective on eight of 14 occasions. Increases in total serum IgG concentration (to a mean peak of 25\u00b73\u2003g\u2003L<jats:sup>\u22121<\/jats:sup>) were not correlated with platelet response. There was no evidence of seroconversion to virus markers, or of alteration in renal function, following Vigam\u2010S infusion. Most adverse events were mild and transient; however, three patients had severe headache and vomiting (possible aseptic meningitis syndrome) and one had marked superficial thrombophlebitis. Therefore Vigam\u2010S provides effective and well tolerated therapy in the management of adults with ITP although individual patient response remains difficult to predict.<\/jats:p>","DOI":"10.1046\/j.1365-3148.2001.00281.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:28:54Z","timestamp":1047504534000},"page":"37-44","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vigam\u2010S, a solvent\/detergent\u2010treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura"],"prefix":"10.1111","volume":"11","author":[{"given":"A. C.","family":"Newland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Cavenagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Copplestone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"3","volume-title":"Intravenous Immunoglobulins in Immunodeficiency Syndromes and Idiopathic Thrombocytopenic Purpura","author":"Barandun S.","year":"1985"},{"issue":"1","key":"e_1_2_6_3_1","first-page":"36","article-title":"Management of chronic immune thrombocytopenic purpura in children and adults","volume":"35","author":"Blanchette V.S.","year":"1998","journal-title":"Seminars in Haematology"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb04894.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb03029.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1999.7740204.x"},{"key":"e_1_2_6_7_1","volume-title":"CPMP\/BPWP\/859\/95","author":"CPMP.","year":"1997"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.8.1056"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210013271416"},{"key":"e_1_2_6_10_1","article-title":"Human normal immunoglobulin for intravenous administration","volume":"918","author":"European Pharmacopoeia.","year":"1994","journal-title":"Monograph"},{"key":"e_1_2_6_11_1","first-page":"33","article-title":"The pharmacokinetics of immunoglobulin G after intravenous infusion: a comparison of two preparations","volume":"7","author":"Gascoigne E.W.","year":"1996","journal-title":"British Journal of Clinical Research"},{"key":"e_1_2_6_12_1","first-page":"461","article-title":"Safety and efficacy of an intravenous immunoglobulin (Vigam\u2010S) in primary antibody deficiency: an interim report","volume":"90","author":"Gascoigne E.W.","year":"1999","journal-title":"Journal of Clinical Immunology"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311807"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.5.1415.1415"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199412003-00006"},{"key":"e_1_2_6_16_1","first-page":"43","volume-title":"Intravenous Immunoglobulin Therapy; Clinical Benefits and Future Prospects","author":"Imbach P.A.","year":"1995"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00633464"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7069.1400"},{"key":"e_1_2_6_19_1","first-page":"203","volume-title":"Clinical Use of Intravenous Immunoglobulins","author":"Newland A.C.","year":"1986"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.273.23.1865"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93395-P"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-4-199408150-00004"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-3148.2001.00281.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3148.2001.00281.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:41:33Z","timestamp":1697568093000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-3148.2001.00281.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["10.1046\/j.1365-3148.2001.00281.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-3148.2001.00281.x","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]},"assertion":[{"value":"2001-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}